Physician profile
Devmith Gajadeera
NPI 1760832372
$2,198.56
in general payments reported to CMS, 2019-2025
14 companies · $883 in 2025
The $883 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $329 · 2024: $987 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $582.38 | 2023-2025 | Airsupra, Tezspire, Farxiga |
| Lilly USA, LLC | $272.50 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $250.00 | 2024-2025 | Krystexxa, Repatha |
| Abbvie INC. | $246.64 | 2023-2025 | |
| Exact Sciences Corporation | $160.42 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bioventus LLC | $133.38 | 2025 | Xcell |
| Phathom Pharmaceuticals, INC. | $132.54 | 2024 | Voquezna |
| Janssen Biotech, INC. | $122.09 | 2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $118.70 | 2024 | Shingrix, Arexvy |
| Myriad Women'S Health, INC. | $68.31 | 2023 | Myrisk |
| Novo Nordisk INC | $58.76 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $19.79 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Verona Pharma, INC. | $17.78 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.27 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devmith Gajadeera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.